Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia

Table 2

Comparison of clinical efficacy between the two groups [n (%)].

Group	n	Significant effect	Valid	Invalid	Total efficiency
Control group	50	15	24	11	39 (78.00)
Experimental group	50	16	25	9	41 (82.00)
t value	—	—	—	—	3.827
value	—	—	—	—	> 0.05